* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)
* Praluent was associated with a 15% lower risk of death from any cause (hazard ratio [HR] 0.85; 95% confidence interval [CI], 0.73 to 0.98)(1)
* Additional analyses, including mortality, to be presented at upcoming American Heart Association Scientific Sessions, November 10-12
PR Newswire
PARIS and TARRYTOWN, N.Y., Nov. 7, 2018
